Marvin Meyers, Ph.D.
Chemical Biology Program
CHEM 3100: Chemical Literature, CHEM 4470/5470: Medicinal Chemistry
B.A. in Chemistry, Dordt College, 1996
Ph.D. in Chemistry. University of Illinois at Urbana-Champaign, 2000
Medicinal Chemistry, Synthetic Organic Chemistry, Chemical Biology, Pharmacology, Drug Discovery
In our lab, we practice the art of medicinal chemistry. We use synthetic organic chemistry to design and prepare new compounds, which are analyzed by our collaborators to assess their biological properties. Using medicinal chemistry and structure-based drug design principles, we optimize the potency, pharmacokinetics, and safety profiles of compounds with the ultimate goal of identification of candidate drugs for clinical trials. The discoveries we make can also teach us about the biology of disease, how things work at a biomolecular level in living systems. We can use small molecules as chemical probes to modulate biological systems, define molecular pathways, and identify new targets for drug discovery.
We are especially interested in finding new drugs for infectious diseases. We are actively working on malaria, cryptosporidiosis, tuberculosis, herpes simplex virus, hepatitis B virus, and cryptococcal meningitis. These diseases kill millions of people annually and are particularly devastating to the poorest of the poor living in the developing world. We also have projects working on rare diseases such as FSHD (a type of muscular dystrophy) and infant short gut syndrome, as well as for certain types of cancer.
To read more details about our lab and these projects, please see our group website at www.meyerschemlab.com.
Labs and Facilities
Monsanto Hall 007, 111 and 218
Publications and Media Placements
1. 4-Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2-Aryl-N-(4-arylpyrrolidin-3-yl)acetamides. Meyers MJ, et al. ACS Med Chem Lett. 2019, 10(6):966-971. doi: 10.1021/acsmedchemlett.9b00123.
2. Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. Karpova D, et al. J Clin Invest. 2019, 130:2745-2759. doi: 10.1172/JCI124738.
3. 4-Aryl Pyrrolidines as a Novel Class of Orally Efficacious Antimalarial Agents. Part 1: Evaluation of 4-Aryl- N-benzylpyrrolidine-3-carboxamides. Meyers MJ, , et al. J Med Chem. 2019, 62(7):3503-3512. doi: 10.1021/acs.jmedchem.8b01972.
4. Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of Neuroreceptor Activity. Montoya MC, et al. ACS Infect Dis. 2018, 4(4):499-507. doi: 10.1021/acsinfecdis.7b00157.
5. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box. Jumani RS, et al. Antimicrob Agents Chemother. 2018, 62(4). doi: 10.1128/AAC.01505-17.
6. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion. Nasamu AS, et al. Science. 2017, 358(6362):518-522. doi: 10.1126/science.aan1478.
7. Evaluation of spiropiperidine hydantoins as a novel class of antimalarial agents. Meyers MJ, et al. Bioorg Med Chem. 2015, 23(16):5144-50. doi: 10.1016/j.bmc.2015.02.050.
8. Evaluation of aminohydantoins as a novel class of antimalarial agents. Meyers MJ, et al. ACS Med Chem Lett. 2014, 5(1):89-93. doi: 10.1021/ml400412x.
Complete List of Publications